Beacon Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeBeacon Therapeutics
Beacon Therapeutics logo

Beacon Therapeutics

0 followers

AGTC

Performance

About Beacon Therapeutics

Beacon Therapeutics is a clinical-stage biotechnology company focused on restoring and preserving vision through ophthalmic gene therapy. The company concentrates on blinding retinal diseases such as X-linked retinitis pigmentosa, dry age-related macular degeneration, and cone-rod dystrophy, employing AAV-based gene therapies. Headquartered with emphasis on ocular indications, Beacon aims to translate scientific innovation into meaningful patient outcomes through ongoing clinical trials and partnerships. The organization positions itself at the forefront of gene therapy for eye diseases, driven by a mission to save and restore sight for individuals affected by inherited retinal disorders.

Recent News

Recent Deals

Key Team Members

Abraham Scaria

Chief Scientific Officer

Lance Baldo

Chief Executive Officer

Tom Biancardi

Chief Financial Officer

Daniel C. Chung

Chief Medical Officer

Darin Curtiss

Global Vice President, Clinical Development

Key Facts

HQ Location

Alachua, United States

Founded

2008

Employees

51 - 200

Status

Public

Website

https://beacontx.com